UroGen to Present at March 2018 Investor Conferences
Get Alerts URGN Hot Sheet
Join SI Premium – FREE
RA’ANANA, Israel and NEW YORK, March 07, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ: URGN) today announced that management plans to present at two investor conferences in March 2018:
- Cowen & Company 38th Annual Health Care ConferenceTuesday, March 138:00AM Eastern TimeBoston, MA
- Oppenheimer 28th Annual Healthcare ConferenceWednesday, March 219:45AM Eastern TimeNew York, NY
A live audio webcast of each event will be available on the Investors section of UroGen's website, www.urogen.com. A replay of each webcast will be available on the website for approximately two weeks.
About UroGen Pharma Ltd.
UroGen Pharma Ltd. (Nasdaq: URGN) is a clinical-stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology. The Company has developed RTGel™, a proprietary sustained release, hydrogel-based formulation for potentially improving therapeutic profiles of existing drugs. UroGen Pharma's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen Pharma's lead product candidates, MitoGel™ and VesiGel™, are designed to potentially remove tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma and bladder cancer. UroGen Pharma is headquartered in Ra’anana, Israel and maintains a corporate office in New York City.
UROGEN CONTACTS:
Christine CassianoCorporate Affairs Officer [email protected] 714-552-0326 Or
Kate BechtoldDirector, Corporate Communications & Investor Relations[email protected] 914-552-0456
Source: UroGen Pharma Ltd.Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UroGen Pharma (URGN) PT Raised to $58 at Guggenheim
- Battery X Metals Appoints Lithium-Ion Battery and Electric Vehicle Entrepreneur William Fan as President to Advance Development of Its Patent-Pending Lithium-Ion Battery Rebalancing Technology Platfor
- Bayport Management Ltd Unaudited Financial Statements June 2026
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
Cowen & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share